IL-10 Plays a Pivotal Role in Tamoxifen-Induced Spasmolytic Polypeptide-Expressing Metaplasia in Gastric Mucosa
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Gastric cancer evolves in the pathologic mucosal milieu, and its development is characterized by both the loss of acid-secreting parietal cells and mucosal cell metaplasia, called spasmolytic polypeptide-expressing metaplasia (SPEM). Cytokines, such as interleukin (IL)-10, IL-1β, and IL-6, play a key role in gastric carcinogenesis. However, changes in the cytokine profile of SPEM have not been evaluated. Methods: To induce SPEM in mouse stomachs, C57BL/6 mice were intraperitoneally injected with tamoxifen and sacrificed at 3, 10, and 21 days after treatment. RNA-sequencing (RNA-seq) and a multiplex bead array were used to measure cytokines in the stomachs of tamoxifen-treated/control mice. Results: The administration of tamoxifen led to the rapid development and histological normalization of SPEM 3 and 10 days after administration, respectively. RNA-seq revealed that the expression of IL-10 was decreased 3 days after tamoxifen administration. The multiplex assay identified a significant decline in IL-10 levels 3 days after tamoxifen treatment (58.38±34.44 pg/mL vs 94.09±4.98 pg/mL, p=0.031), which normalized at 10 and 21 days after tamoxifen treatment. Immunofluorescence staining confirmed that IL-10 expression was markedly decreased at the time of SPEM development and subsequently returned to normal, accompanied by a reversal in histologic changes. Conclusions: IL-10 may play a pivotal role in the tamoxifen-induced acute development of gastric SPEM.
Abstract
Background/Aims: Gastric cancer evolves in the pathologic mucosal milieu, and its development is characterized by both the loss of acid-secreting parietal cells and mucosal cell metaplasia, called spasmolytic polypeptide-expressing metaplasia (SPEM). Cytokines, such as interleukin (IL)-10, IL-1β, and IL-6, play a key role in gastric carcinogenesis. However, changes in the cytokine profile of SPEM have not been evaluated. Methods: To induce SPEM in mouse stomachs, C57BL/6 mice were intraperitoneally injected with tamoxifen and sacrificed at 3, 10, and 21 days after treatment. RNA-sequencing (RNA-seq) and a multiplex bead array were used to measure cytokines in the stomachs of tamoxifen-treated/control mice. Results: The administration of tamoxifen led to the rapid development and histological normalization of SPEM 3 and 10 days after administration, respectively. RNA-seq revealed that the expression of IL-10 was decreased 3 days after tamoxifen administration. The multiplex assay identified a significant decline in IL-10 levels 3 days after tamoxifen treatment (58.38±34.44 pg/mL vs 94.09±4.98 pg/mL, p=0.031), which normalized at 10 and 21 days after tamoxifen treatment. Immunofluorescence staining confirmed that IL-10 expression was markedly decreased at the time of SPEM development and subsequently returned to normal, accompanied by a reversal in histologic changes. Conclusions: IL-10 may play a pivotal role in the tamoxifen-induced acute development of gastric SPEM.
참고문헌 (24)
- Bordi C, "Structure and function of endocrine cells in the oxyntic (acid-secreting) mucosa of human stomach", Scand J Gastroenterol Suppl, 166, pp.115~121 (1989)
- Goldenring JR, "Oxyntic atrophy, metaplasia, and gastric cancer", Prog Mol Biol Transl Sci, 96, pp.117~131 (2010)
- Weis VG, "Current understanding of SPEM and its standing in the preneoplastic process", Gastric Cancer, 12, pp.189~197 (2009)
- Fox JG, "Inflammation, atrophy, and gastric cancer", J Clin Invest, 117, pp.60~69 (2007)
- Nozaki K, "A molecular signature of gastric metaplasia arising in response to acute parietal cell loss", Gastroenterology, 134, pp.511~522 (2008)
- Petersen CP, "Macrophages promote progression of spasmolytic polypeptide-expressing metaplasia after acute loss of parietal cells", astroenterology, 146, pp.1727~1738.e8 (2014)
- Nam KT, "Spasmolytic polypeptide-expressing metaplasia (SPEM) in the gastric oxyntic mucosa does not arise from Lgr5-expressing cells", Gut, 61, pp.1678~1685 (2012)
- Abdiev S, "Helicobacter pylori infection and cytokine gene polymorphisms in Uzbeks", Nagoya J Med Sci, 72, pp.167~172 (2010)
- Sugimoto M, "Influence of interleukin polymorphisms on development of gastric cancer and peptic ulcer", World J Gastroenterol, 16, pp.1188~1200 (2010)
- Jung HC, "Helicobacter pylori induces an array of pro-inflammatory cytokines in human gastric epithelial cells: quantification of mRNA for interleukin-8, -1 alpha", beta, granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein-1 and tumour necrosis factor-alpha, 1997, pp.12, 473~480
- Ramis IB, "Polymorphisms of the IL-6, IL-8 and IL-10 genes and the risk of gastric pathology in patients infected with Helicobacter pylori", J Microbiol Immunol Infect, 50, pp.153~159 (2017)
- Konturek PC, "Hahn EG. H. pylori infection, atrophic gastritis, cytokines, gastrin, COX-2, PPAR gamma and impaired apoptosis in gastric carcinogenesis", Med Sci Monit, 9, pp.SR53~SR66 (2003)
- Howlett M, "IL-11 is a parietal cell cytokine that induces atrophic gastritis", Gut, 61, pp.1398~1409 (2012)
- Ogawa M, "Omeprazole treatment ameliorates oxyntic atrophy induced by DMP-777", Dig Dis Sci, 51, pp.431~439 (2006)
- Weis VG, "Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression", Gut, 62, pp.1270~1279 (2013)
- Lefebvre O, "Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein", Science, 274, pp.259~262 (1996)
- Huh WJ, "Tamoxifen induces rapid, reversible atrophy, and metaplasia in mouse stomach", Gastroenterology, 142, pp.21~24.e7 (2012)
- Chandanos E, "Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden", Br J Cancer, 95, pp.118~122 (2006)
- Polin SA, "The effect of tamoxifen on the genital tract", Cancer Imaging, 8, pp.135~145 (2008)
- Giraud AS, "Differentiation of the gastric mucosa IV: role of trefoil peptides and IL-6 cytokine family signaling in gastric homeostasis", Am J Physiol Gastrointest Liver Physiol, 292, pp.G1~G5 (2007)
- De Vita F, "Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies", Cancer, 86, pp.1936~1943 (1999)
- Yamaoka Y, "Natural history of gastric mucosal cytokine expression in Helicobacter pylori gastritis in Mongolian gerbils", Infect Immun, 73, pp.2205~2212 (2005)
- Bodger K, "Gastric mucosal secretion of interleukin-10: relations to histopathology, Helicobacter pylori status, and tumour necrosis factor-alpha secretion", Gut, 40, pp.739~744 (1997)
- Dennis KL, "Current status of interleukin-10 and regulatory T-cells in cancer", Curr Opin Oncol, 25, pp.637~645 (2013)